Hearing Date of Thalidomide Lawsuit in Germany announced

Food and Healthcare Press Releases Tuesday February 14, 2017 08:40
COLOGNE, Germany--14 Feb--PRNewswire/InfoQuest

60 years after the market launch of Contergan (active ingredient: thalidomide), the greatest pharmaceutical scandal in the Federal Republic of Germany continues to boil. A lawsuit will be heard in the Bonn Regional Court at 12:00 hrs on 15.2.2017 that is more explosive than appears at first sight.

The Contergan victim Andreas Meyer, who was born without arms or legs and is confined to a wheelchair, is suing the former member of the Management Board of the Contergan Foundation, Attorney Karl Schucht, for injunction and rectification.

In a letter to the members of the Family Affairs Committee of the German Federal Parliament, Schucht had asserted that Meyer, as an expert witness at a public hearing of the Committee, had publicly stated various untruths about events connected with the Contergan Foundation.

Meyer had said among other things that for 30 years the Contergan (thalidomide) manufacturer Grunenthal GmbH had had access to the medical files of the Contergan victims in the Contergan Foundation. In addition, Grunenthal had also paid the Foundation's medical experts.

In his letter, Schucht asserted to the contrary that Grunenthal had at no time had access to the medical files of the Contergan victims, but that the files were always kept by the Contergan Foundation. Further, he asserted that the experts of the Medical Commission were always paid from the funds of the Contergan Foundation.

Why so explosive? Because if Meyer wins the lawsuit it will mean that not only Schucht had told untruths to the members of Parliament. No, the Federal Government had also told untruths to Parliament.

Because the Federal Ministry of Family Affairs, which has been responsible for supervision of the Contergan Foundation since 1972, stated in a reply to a Minor Interpellation by the Parliamentary Group Die Linke that Schucht's letter also expressed the opinion of the Federal Government.

A pivotal question, according to Meyer, is the double role of Attorney Herbert Wartensleben who has also been invited as a witness by the Bonn Regional Court. From 1972 until the end of 2003, Wartensleben was not only Chairman of the Medical Commission of the Contergan Foundation, which judges whether a victim is or is not damaged by Contergan and also evaluates the degree of damage – on the basis of which the amount of the Contergan pension is assessed, for example. Since the Contergan trial, Wartensleben acted again and again as the legal representative of Grunenthal in cases relating to Contergan; most recently in 2007 in the lawsuits concerning the two-part ARD feature film "Eine einzige Tablette" (One single tablet).

"The case deals with the question of whether the Contergan Foundation was, or perhaps still is, an undercover subsidiary of Grunenthal under the eyes of the Federal Government," said Meyer.

Meyer will be represented by Prof. Dr. Jan Hegemann from the law firm Raue Rechtsanwälte LLP in Berlin. Attorney Prof. Dr. Jan Hegemann already successfully represented Meyer in 2009 in the case of Meyer's call to boycott the products of Dalli-Werke, Mäurer & Wirtz and 4711 – companies belonging to Grunenthal's owner. Attorney Karl Schucht will be represented by Attorneys Gernot Lehr and Tobias Würkert LLM from the Bonn office of the law firm Redeker Sellner Dahs. For Meyer, this is significant. The founder of that law firm, Prof. Dr. Hans Dahs senior who died in 1972, represented the late owner of Grunenthal, Dr. Hermann Wirtz senior, in the Contergan trial.

Place and date of the court hearing
Date: 15.2.2017
Time: 12:00 hrs
Place: Bonn Regional Court, Wilhelmstrasse 21, 53111 Bonn
Room: Courtroom S. 0.15 (Saalbau)
You can find further important information at the following link:
http://www.gruenenthal-opfer.de/Materials_Meyer_vs_Schucht_15_2_2017
Contact:
Federation of Thalidomide Sufferers and Grunenthal Victims
c/o Mr Andreas Meyer (Chairman)
Dohmengasse 7 , 50829 Koln
Email: bcg-brd-dachverband@gmx.de
Website: http://www.Gruenenthal-opfer.de
Mobile: +49 (0)172 / 2905974
Source: Federation of Thalidomide Sufferers and Grunenthal Victims

Latest Press Release

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands...

2018 Empire State Building Run-Up Lottery Registration Opens on November 14, 2017

Runners must enter by December 10 for a chance to participate in the 41st Annual Run-Up on Wednesday, February 7, 2018, at 8:00 p.m. Empire State Realty Trust, Inc. (NYSE: ESRT) today announced that lottery registration for the 2018 Empire State...

Alpinion Medical Systems Launches E-CUBE 8, the New Ultrasound Diagnostic System

One of South Korea's global medical device manufacturers, Alpinion Medical Systems introduced its new E-CUBE 8, the latest and last addition to the E-CUBE lineup. The E-CUBE 8 is a smart, reliable product that ensures high performance with outstanding...

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk...

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from...

Related Topics